Biomx Ltd is a biotechnology company focused on developing innovative therapies that harness the power of bacteriophage, a type of virus that specifically targets and kills bacteria. The company primarily aims to treat diseases caused by specific bacterial infections, particularly those that are resistant to traditional antibiotics. By utilizing phage-based treatments, Biomx is working to address significant medical challenges in various conditions, including gastrointestinal disorders and other diseases driven by harmful bacteria, with the ultimate goal of improving patient outcomes and enhancing the overall landscape of antimicrobial therapies. Read More
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
In a significant step toward national deployment, Signal Advance Inc. (OTCID: SIGL) leads federal cybersecurity engagement with breakthrough Analog Guard® Technology, Recently the company held private meetings with U.S. Congressmen Pete Sessions (TX) and Don Bacon (NE) —two influential voices on national defense and cybersecurity. Discussions focused on the use of the company’s patented Analog Guard® technology across federal, defense, and critical infrastructure systems, opening the door to potential collaborations with government agencies and defense contractors .
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Trading of BiomX Inc. (NYSE: PHGE) shares surged today following the company's announcement that it has successfully dosed the first patient in its Phase 2b trial evaluating BX004 for cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections. The stock movement seems to reflect growing investor confidence in the company's phage therapy platform and its potential to address significant unmet medical needs.
